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moderate AD. ( J Am Acad Dermatol 2016;75:297-305.)
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d Peripheral leukocytes of patients with
atopic dermatitis have increased
phosphodiesterase activity.
d OPA-15406, a new topical inhibitor of
phosphodiesterase-4, provided rapid
and sustained relief of patient-reported
pruritus and significant overall
improvement of atopic dermatitis.
d OPA-15406-mediated selective
phosphodiesterase-4 inhibition may
provide an effective treatment modality
for patients with atopic dermatitis.This study was conducted
in compliance with Inter-
national Conference on
Harmonization good clinical
practice guidelines for con-
ducting, recording, and re-
porting clinical trials, and
for archiving essential docu-
ments.1 Consistent with
ethical principles for the pro-
tection of human research
subjects,2 no trial procedures
were performed on trial
candidates until written con-
sent had been obtained. The
informed consent form,
protocol, and amendments
for the study were submitted
to and approved by the institutional review board or
independent ethics committee for each respective
trial site or country.
Atopic dermatitis (AD) is a chronic inflammatory
skin condition characterized by pruritic erythema-
tous skin lesions and associated cutaneous
dysfunction (eg, barrier-disrupted skin).3 The onset
of AD occurs most commonly between 3 and
6 months of age, with approximately 60% of patients
developing the condition in the first year of life and
90% by 5 years of age.4-6 The majority of affected
individuals have resolution of disease during
childhood, although 10% to 30% of patients maintain
the condition throughout their lives, and a small
number of others develop first symptoms as
adults.4,7 It has been estimated that approximately
18 million people are living with AD in the United
States, many with undiagnosed disease.8
AD cannot be cured, but prompt and effective
management can greatly improve both the
symptoms and quality of life of affected individuals.
According to guidelines from the American Academy
of Dermatology,4 when emollient use and good skin
care are insufficient to control AD, pharmacologic
treatment should start with mild- to moderate-
potency topical corticosteroids. If this approach is
unsuccessful, treatment with calcineurin inhibitors
can be considered. For severe AD that remains
refractory to topical agents, treatment may beintensified to ultraviolet pho-
totherapy and systemic im-
munomodulators. Although
current pharmacotherapeu-
tic approaches have proven
to be efficacious in clinical
trials,4,9-13 each has limi-
tations. Extended use of
topical corticosteroids is
associated with cutaneous
atrophy3 and can sometimes
have systemic side effects,
such as suppression of
the hypothalamic-pituitary-
adrenal axis, especially in
children.14 Available topical
calcineurin inhibitors carry
boxed warnings posingsome limitations on their long-term use, based on
possible associations with lymphomas and skin
malignancies in animal studies.15,16 However,
clinical studies in human beings have failed to
identify an association between topical calcineurin
inhibitor use and malignancies,17 with the possible
exception of a very slightly increased risk of skin
lymphomas in patients with severe AD.18
Peripheral blood leukocytes in patients with
AD have increased phosphodiesterase-4 (PDE4)
activity,19-21 which has been associated with higher
production of the proinflammatory mediators tumor
necrosis factor-alfa, interleukin (IL)-17, IL-22, and
interferon-g and lower production of the anti-
inflammatory mediator IL-10.21 In pharmacologic
analyses, the new chemical entity OPA-15406
exhibited highly selective inhibitory activity against
PDE4 subtypes, particularly subtype B (IC50 = 11.2
nmol/L), and improved skin condition in relevant
animal models of AD (unpublished data). This report
evaluates the clinical activity, pharmacokinetics, and
tolerability of 2 concentrations of OPA-15406
ointment in adult and adolescent patients with mild
or moderate AD.
METHODS
Study design
This was a phase-II, randomized, double-blind,
vehicle-controlled, parallel-group study. Eligible
Abbreviations used:
AD: atopic dermatitis
BSA: body surface area
DLQI: Dermatology Life Quality Index
EASI: Eczema Area and Severity Index
IGA: Investigator Global Assessment of Disease
Severity
IL: interleukin
PDE4: phosphodiesterase-4
VAS: visual analog scale
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Hanifin et al 299patients were between the ages of 10 and 70 years
and had a diagnosis of AD according to the criteria
of Hanifin and Rajka22 and Rajka and Langeland,23 a
baseline Investigator Global Assessment of Disease
Severity (IGA) score of 2 (mild) or 3 (moderate), and
at least a 3-year history of the disease. Total body
surface area (BSA)24 affected by AD at baseline could
not be more than 40%, but had to be at least 5%. The
face, neck, and head were not treated under the
protocol. Patients were required to have had a
previous positive but inadequate response to 1 or
more standard therapies for AD or were currently
unable to use a previously successful treatment.
Exclusion criteria included having received systemic
therapy or phototherapy within 28 days, or use of
topical corticosteroids or calcineurin inhibitors
within 7 days of study entry.
Eligible patients were randomized into 3 treat-
ment groups to receive OPA-15406 0.3% (wt/wt),
OPA-15406 1% (wt/wt), or vehicle on a double-blind
basis. During the 8-week treatment period, patients
were instructed to apply a thin film of study ointment
to affected areas twice daily, with applications
occurring approximately 12 hours apart. The amount
applied was approximately 1 g of ointment per every
4% BSA to be treated. Assessments were conducted
pretherapy (baseline) and at weeks 1, 2, 4, 6, and 8.
Thirty dermatology-specialty research centers
participated in the study from the United States
(ClinicalTrials.gov identifier: NCT02068352), Poland
(European Clinical Trials Database number:
2013-003899-12), and Australia.Assessments
Patients were assessed at each visit by a
board-certified dermatologist or country-specific
equivalent using the 6-point IGA (0 = no disease to
5 = very severe disease)4 and the Eczema Area and
Severity Index (EASI).25 Patient-reported effects
were based on a 100-mm visual analog scale (VAS)
for pruritus,26 the adult Dermatology Life Quality
Index (DLQI)27 for patients 17 years of age or older,and the Children’s DLQI28 for patients 16 years of age
or younger.
Pharmacokinetics
Nine patients from 6 centers also consented to
provide blood samples at baseline and week 4 for
pharmacokinetic evaluation of OPA-15406 (5 in the
0.3% group and 4 in the 1% group). Blood samples
were collected before and 2, 4, and 8 hours after the
first of the twice-daily doses. Plasma samples were
analyzed by high-performance liquid chromato-
graphy with tandem mass spectrometric detection.
Pharmacokinetic parameters were determined using
noncompartmental analysis performedwith Phoenix
WinNonlin, Version 6.3 (Pharsight Corporation,
Princeton, NJ).
Statistical analysis
Forty patients per treatment group provided more
than 80% power for each comparison of OPA-15406
versus vehicle at a 2-sided significance level 0.05,
assuming response rates of 0.53 and 0.20,
respectively. The primary end point was incidence
of success at week 4 in IGA score, defined as a final
score of 0 or 1 with at least a 2-grade reduction from
baseline. To control the overall type I error rate of
0.05, a 2-step testing procedure was applied:
OPA-15406 1% versus vehicle first, and OPA-15406
0.3% versus vehicle next only if the first test was
statistically significant (P\ .05).
For the primary analysis, patients without an IGA
score at a scheduled visit were treated as
nonresponders for that visit. Comparisons of
incidences of success between each OPA-15406 level
and vehicle were conducted by Cochran-Mantel-
Haenszel test, stratified by geographic region and
age group. The 95% Wald confidence intervals were
calculated for the differences of incidence between
each OPA-15406 concentration level and vehicle.
Subgroup analyses for the primary efficacy variable
were provided by age group (\18 or $18 years),
geographic region, IGA (mild, moderate), and
percent BSA treated (5%-25%,[25%) at baseline.
Change (or percentage change) from baseline in
overall IGA score, EASI score, VAS score, and DLQI
were analyzed using analysis of covariance with
treatment, region, and age group as fixed terms and
baseline score as covariate, based on last observation
carried forward data.
RESULTS
Patients
A total of 121 patients were randomly assigned to
receive OPA-15406 0.3% (n = 41), OPA-15406 1%
(n = 43), or vehicle (n = 37) (Fig 1). All patients
Fig 1. CONSORT flow diagram.
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analyzed for efficacy and safety. Overall, 27 (22%)
patients discontinued prematurely, 10 (24%) in the
OPA-15406 0.3% group, 8 (19%) in the OPA-15406 1%
group, and 9 (24%) in the vehicle group. Three of the
early discontinuations were attributed to adverse
eventspotentially related to study treatment, including
1 case of worsening erythema/pruritus (OPA-15406
0.3%), 1 case of AD exacerbation (vehicle), and 1 case
of application site irritation (vehicle). One protocol-
specified withdrawal occurred because of pregnancy
in a patient who received 30 days of OPA-15406 1%;
the patient subsequently delivered a full-term healthy
baby.
In all, 37 (31%) patients enrolled with an IGA
score of 2 and 84 (69%) patients enrolled with an IGA
score of 3. At baseline, the overall study population
had a mean EASI score of 9.5 6 5.2, a mean VAS
pruritus score of 61.7 6 24.0 mm, and a mean
affected BSA percentage of 13%6 8.6%. Of enrolled
patients, 20% were younger than 18 years of age.
Baseline characteristics were adequately balanced
among treatment groups (Table I).Effectiveness
The prespecified primary end point was the rate
of successful responses on the IGA at week 4.
A successful response was defined as a score of
0 (clear) or 1 (almost clear), with at least a 2-grade
reduction from the baseline score of 2 (mild) or 3
(moderate). At week 4, success rates were 2.7% for
vehicle, 14.6% for OPA-15406 0.3% (P = .0690 vs
vehicle), and 20.9% for OPA-15406 1% (P = .0165 vs
vehicle) (Fig 2, A). No appreciable subgroup
differences were observed in success rate when
analyzed by age, percentage of affected BSA at
baseline, or geographic region (Fig 3), although
patients with a baseline IGA score of 3 demonstrated
a numerically better IGA response rate than those
with a baseline IGA score of 2.
Mean rates at which patients reached an IGA score
of 0 or 1, with or without a 2-grade reduction from
baseline score, were 10.0% for vehicle, 24.4% for
OPA-15406 0.3% (P = .1287 vs vehicle), and
30.2% for OPA-15406 1% (P = .0354 vs vehicle) at
week 4 (Fig 2, B). Whether based on IGA success rate
(Fig 2, A) or an IGA score of 0 or 1 (Fig 2, B), disease
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Fig 2. Clinician-reported outcomes based on Investigator
Global Assessment of Disease Severity (IGA). A, Mean
success rates per visit. A successful response was defined
as an IGA score of 0 or 1 with at least a 2-grade reduction
from baseline. B, Mean rates of an IGA score of 0 or 1
(ie, with or without a 2-grade reduction) per visit. P values
are for comparisons with vehicle. Last observation carried
forward was used to impute missing data.
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OPA-15406 1% group, and early positive responses
were sustained until the end of treatment (week 8)
(Fig 2).
EASI mean scores decreased (indicating disease
improvement) at week 1 in the OPA-15406 1%
treatment group (2.37; P = .0098 vs vehicle), and
this trend was maintained at all subsequent study
time points (Fig 4, A). This translated into a 31.4%
improvement at week 1 (P = .0005 vs vehicle [6.0%]),
a 39.0% change by week 2 (P = .0001 vs vehicle
[3.0%]), and a sustained response through week 8
(Fig 4, B). EASI percentage changes from baseline
were also numerically improved at all time points in
the OPA-15406 0.3% group (P = .0303 OPA-15406
0.3% vs vehicle at week 2), although the treatment
effects were smaller than those observed with
OPA-15406 1%.
In patient-reported assessments, the OPA-15406
1% group exhibited a rapid and sustained improve-
ment in AD-associated pruritus relative to the vehicle
Fig 3. Subgroup analysis of success rate. Shown are the rates (plus 95% confidence intervals
[CI]) at which patients received a score of 0 or 1 and had at least a 2-grade reduction
from baseline (BSL) score within the designated subgroups at week 4. BSA, Body surface area;
CMH, Cochran-Mantel-Haenszel; IGA, Investigator Global Assessment of Disease Severity;
NE, not estimable; RR, responder rate.
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improved from moderate (63.7 6 20.3 mm) to mild
(40.5 6 27.1 mm) within 1 week, representing a
36.4% change from baseline. Improvements in
pruritus were less dramatic in the OPA-15406 0.3%
group. Change from baseline in response to question
1 of the DLQI/Children’s DLQI, ie, ‘‘How itchy,
scratchy and painful has your skin been over the
last week?’’ also demonstrated statistically significant
improvement (P = .0082) in patients treated with
OPA-15406 1% by week 1. Overall, therapy with
OPA-15406 1% resulted in early improvements in
total quality-of-life scores by week 1 (P = .0037 vs
vehicle) (Fig 5, B), representing a 37.2% change from
baseline.
Pharmacokinetic analyses
Among the 9 patients with pharmacokinetics
the percentage of overall BSA treated ranged
from 5% to 33%; 1 of the 9 had more than 25% of
BSA treated. After topical application, plasma
levels of OPA-15406 were low for both the 0.3%
and the 1% formulations on the first day of dosing, asdemonstrated by low maximum plasma concentra-
tion after administration (3.18 and 4.74 ng/mL,
respectively) and area under the curve values (16.0
and 20.7 ng*h/mL, respectively) (Table II).
Pharmacokinetic parameters at week 4 were similar
to those on day 1, indicating no apparent accumu-
lation of active drug after multiple twice-daily
administrations of OPA-15406.
Tolerability
Of the 121 patients enrolled in this study, 62 (51%)
experienced adverse events (18 of 43 [42%] in the
OPA-154061%group, 24of 41 [59%] in theOPA-15406
0.3% group, and 20 of 37 [54%] in the vehicle group).
Of these, 11 (9%) patients experienced adverse
events considered by the investigator to be at least
potentially related to the study treatment (1 of 43 [2%]
in the OPA-15406 1% group, 5 of 41 [12%] in the
OPA-15406 0.3% group, and 5 of 37 [14%] in the
vehicle group).
In all, 26 patients exhibited worsening of their AD,
making this the most frequent adverse event in each
treatment group (Table III). The worsening occurred
Fig 4. Clinician-reported outcomes based on the Eczema
Area and Severity Index (EASI ). A, Numeric least squares
mean change from baseline in EASI score. B, Percentage
improvement from baseline EASI score. P values are for
comparisons with vehicle. Last observation carried
forward was used to impute missing data.
Fig 5. Patient-reported outcomes. A, Mean change from
baseline in visual analog scale (VAS ) pruritus scores per
visit. B, Mean change from baseline in Dermatology Life
Quality Index (DLQI ) and the Children’s DLQI (CDLQI )
per visit. Values on both graphs are least squares
means. P values are for comparisons with vehicle. Last
observation carried forward was used to impute missing
data.
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the OPA-15406 1% group, 8 of 41 [20%] in the
OPA-15406 0.3% group, and 3 of 37 [8%] in the
vehicle group). In 5 patients, the worsening of AD
was assessed as potentially treatment-related
(recorded 3 times in the OPA-15406 0.3% group
and 3 times in vehicle group); notably, none of the
cases of treatment-related worsening of AD were
reported in the OPA-15406 1% group.
The remaining treatment-related adverse events
were yeast infection in 1 patient in the OPA-15406 1%
group (study verbatim: vulvovaginal mycotic
infection) and 1 case each of application site pain,
erythema, and pruritus in the OPA-15406 0.3% group
and application site irritation and pruritus in the
vehicle group. All treatment-related adverse events
were mild to moderate in intensity.
Five adverse events were classified as serious;
none were related to study medication. In the
OPA-15406 0.3% group, there was 1 newly
diagnosed case of multiple sclerosis in a patient
with family history of multiple sclerosis, and 1 case of
abnormal liver function test results (meeting Hy law
criteria) in a patient after acetaminophen/codeinecombination therapy for tooth extraction pain. In the
OPA-15406 1% group, 1 case each of worsening of
depression, giardiasis infection, and splenic rupture
caused by a motor accident was reported.
DISCUSSION
In this study, the PDE4 inhibitor OPA-15406,
applied topically as a 0.3% (wt/wt) or 1% (wt/wt)
ointment, provided therapeutic benefit to patients
with mild to moderate AD. The benefit was
documented by clinician-reported outcomes,
including success rate (based on IGA score) and
percentage change on the EASI score. OPA-15406
treatment was also associated with improvements in
patient-reported outcomes, notably improvements
in VAS pruritus scores, with significant treatment
effects observed for the 1% formulation relative to
vehicle at most time points in the study. Pruritus, a
hallmark of AD, can lead to skin damage by
Table II. Pharmacokinetics
OPA-15406 0.3% OPA-15406 1%
Day 1
N 4 4
Cmax, ng/mL (SD) 3.18 (2.79) 4.74 (5.51)
tmax, median h
(minimum,
maximum)
4.01 (2.00, 4.07) 4.06 (4.00, 7.50)
AUC0e8h,
ng*h/mL (SD)
16.0 (13.6) 20.7 (22.5)
Week 4
N 5 4
Cmax, ng/mL (SD) 2.94 (2.98) 1.38 (0.554)
tmax, median h
(minimum,
maximum)
4.15 (0, 8.00) 4.98 (0, 8.00)
AUC0e8h,
ng*h/mL (SD)
20.1 (22.3) 8.58 (3.35)
Plasma samples were collected from a subset of patients on days 1
and 29 (week-4 visit) and subjected to pharmacokinetic analysis
(see ‘‘Methods’’ section).
AUC0e8h, Area under the concentration curve from 0-8 hours;
Cmax, maximum plasma concentration after administration;
tmax, time to reach Cmax.
Table III. Tolerability
OPA-15406 0.3%,
N = 41
n (%)
OPA-15406 1%,
N = 43
n (%)
Vehicle,
N = 37
n (%)
Worsening atopic
dermatitis
11 (26.8) 7 (16.3) 8 (21.6)
Nasopharyngitis 3 (7.3) 1 (2.3) 3 (8.1)
Headache 2 (4.9) 3 (7.0) 0 (0.0)
Worsening pruritus 3 (7.3) 0 (0.0) 1 (2.7)
Upper respiratory
tract infection
3 (7.3) 1 (2.3) 0 (0.0)
Vomiting 0 (0.0) 2 (4.7) 1 (2.7)
Toothache 0 (0.0) 1 (2.3) 2 (5.4)
Impetigo 0 (0.0) 2 (4.7) 0 (0.0)
Diarrhea 0 (0.0) 2 (4.7) 0 (0.0)
Excoriation 0 (0.0) 0 (0.0) 2 (5.4)
Includes treatment-related and -unrelated adverse events occurring
in $4% of patients in any treatment group.
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infection, which further aggravates the disease.29
Nocturnal scratching is one of the most common
symptoms of AD and often results in sleep
disturbances and dramatic impairment in quality of
life, especially in children. Thus, a new treatment
modality with a direct positive impact on
limiting pruritus, while simultaneously decreasing
inflammation in affected skin, has the potential to
substantially improve therapeutic options for the
management of AD.Several other features of OPA-15406 therapy were
noted in this study. First, the anti-inflammatory
and antipruritic effects had rapid onset, with statis-
tically significant differences from vehicle in some
parameters within 1 week of treatment. In general,
the positive effects of OPA-15406 were sustained
through the week-8 visit, but the differences
between active and vehicle arms diminished slightly
as skin condition improved in the vehicle group over
time, presumably as a result of the emollients in
the ointment base. Second, in all assessments,
OPA-15406 1% exhibited better clinical and
patient-reported outcomes than OPA-15406 0.3%,
suggesting a clear dose response. Finally, the nature
and number of treatment-related adverse events,
combined with the negligible systemic exposure
after OPA-15406 application, indicated an overall
favorable tolerability profile for this new topical
agent.
Our study has limitations because of the com-
pound’s early developmental stage, eg, the relatively
small number of enrolled patients, and it is difficult to
predict how OPA-15406 will compare with
topical calcineurin inhibitors, topical corticosteroids,
or other PDE4 inhibitors. Moreover, further
investigations in pediatric patient populations (age
\10 years) will be needed. Nonetheless, the
consistent and beneficial effects observed in this
study support further evaluation of OPA-15406 1%
ointment for the treatment of AD in large randomized
phase-III trials.
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